What is the latest AGARWALEYE stock price?
The latest stored price for AGARWALEYE is Rs 500.20 as of 2026-08-21.
gimli
AGARWALEYE stock AI analysis
AGARWALEYE Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
DR AGARWALS HEALTH CARE L is a small-cap stock in Healthcare. This Gimli page shows the latest available AGARWALEYE price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹500.20
1W return
-1.24%
1M return
+2.96%
3M return
+3.97%
6M return
+12.18%
1Y return
+9.87%
Market cap
₹15,855.49 cr
PE
128.53
PB
7.48
ROE
+6.10%
ROCE
+9.32%
RSI
49.26
Turnover
₹22.67 cr
Why it can matter in screens
- Momentum: AGARWALEYE is above 50DMA, above 200DMA; RSI is 49.26.
- Returns: 1D -0.58%, 1W -1.24%, 1M +2.96%, 3M +3.97%, 1Y +9.87%.
- Trend levels: 52W high ₹567.75, 52W low ₹437.00, off high -11.90%.
- Liquidity: latest turnover is ₹22.67 cr; volume vs 20D is +0.17%.
- Valuation/profitability: PE 128.53, PB 7.48, ROE +6.10%, ROCE +9.32%.
- Growth: 3Y sales CAGR +26.95%, 3Y profit CAGR +12.27%.
Quick Answers
Is AGARWALEYE above its 50DMA and 200DMA?
AGARWALEYE is above 50DMA, above 200DMA. The latest 50DMA is 487.32 and the latest 200DMA is 473.47.
What are AGARWALEYE PE, ROE and ROCE?
AGARWALEYE has PE 128.53, ROE +6.10%, and ROCE +9.32% in Gimli's latest available snapshot.
How has AGARWALEYE performed recently?
AGARWALEYE has returned +2.96% over 1 month, +3.97% over 3 months, and +9.87% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 614.02 cr | 176.82 cr | 45.23 cr | 1.43 |
| 2026-03-31 | 564.11 cr | 175.38 cr | 39.71 cr | 1.25 |
| 2025-12-31 | 529.86 cr | 154.64 cr | 33.74 cr | 1.07 |
| 2025-09-30 | 315.79 cr | 144.07 cr | 4.68 cr | nan |
| 2025-06-30 | 487.42 cr | 141.25 cr | 30.05 cr | 0.95 |
| 2025-03-31 | 460.22 cr | 143.92 cr | 32.57 cr | 1.04 |
| 2024-12-31 | 430.72 cr | 127.52 cr | 22.34 cr | 0.71 |
| 2024-09-30 | 415.49 cr | 118.33 cr | 16.58 cr | nan |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 2,080.08 cr | 615.34 cr | 133.19 cr | nan |
| 2025-03-31 | 1,711.00 cr | 499.38 cr | 83.46 cr | 2.80 |
| 2024-03-31 | 1,327.67 cr | 406.56 cr | 83.06 cr | 2.63 |
| 2023-03-31 | 1,016.48 cr | 283.86 cr | 94.10 cr | 2.98 |
| 2022-03-31 | 371.96 cr | 196.12 cr | -1.47 cr | 1.19 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 3,941.75 cr | 90.55 cr | 1,066.20 cr | 2,119.70 cr |
| 2025-03-31 | 3,671.57 cr | 103.61 cr | 960.91 cr | 1,926.82 cr |
| 2024-03-31 | 2,752.82 cr | 111.75 cr | 966.44 cr | 1,379.51 cr |
| 2023-03-31 | 1,825.17 cr | 126.98 cr | 857.35 cr | 659.07 cr |
| 2022-03-31 | 1,026.13 cr | 99.62 cr | 618.56 cr | 233.82 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 518.99 cr | 58.41 cr | n/a |
| 2025-03-31 | 357.13 cr | 36.23 cr | n/a |
| 2024-03-31 | 346.00 cr | 113.67 cr | n/a |
| 2023-03-31 | 233.11 cr | 75.31 cr | n/a |
| 2022-03-31 | 164.33 cr | 93.75 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +32.34% | +57.96% | +7.72% | +6.02% | +1.98% | +0.00% |
| 2026-03-31 | +32.36% | +57.94% | +7.83% | +5.87% | +1.87% | +0.00% |
| 2025-12-31 | +32.39% | +58.06% | +7.78% | +5.77% | +1.77% | +0.00% |
| 2025-09-30 | +32.42% | +58.13% | +7.92% | +5.85% | +1.52% | +0.00% |
| 2025-06-30 | +32.42% | +59.26% | +6.44% | +4.91% | +1.88% | +0.00% |
| 2025-03-31 | +32.45% | +60.62% | +5.21% | +3.84% | +1.72% | +0.00% |
| 2025-02-03 | +32.45% | +56.97% | +5.10% | +3.18% | +5.49% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze DR AGARWALS HEALTH CARE L with valuation, momentum and industry peers
- Compare AGARWALEYE with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare AGARWALEYE with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.